Literature DB >> 10337490

High-performance subtractive hybridization of cDNAs by covalent bonding between specific complementary nucleotides.

S Y Ying1, S Lin.   

Abstract

We have developed an improved subtractive hybridization method that provides a fast, simple and reliable isolation of desired different sequences from two compared DNA libraries, one of which contains all unwanted homologues (subtracter) and another contains certain desired heterologues (tester). The DNA library can be made from either mRNA or genomic DNA. An excess amount of modified subtracter DNA from control cells was generated by chemical carboxylation of the pyrimidines to provide covalent affinity to the purines of a natural tester DNA. Hybridization of the control subtracter and the experimental tester DNA was performed with a heat-melting and then cool-reassociation technique. The desired different sequences remained in the form of hydrogen-bonded, homologous sequences of both libraries covalently bonded to each other, resulting in no separation during PCR and cloning. Consequently, the DNA sequences obtained from the covalent homology subtraction represent the nucleotide sequences abundant in the tester but rare in the subtracter library.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10337490     DOI: 10.2144/99265rr06

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  2 in total

1.  Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

2.  Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.

Authors:  Marvin Rubenstein; Paulus Tsui; Patrick Guinan
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.